Pfizer has entered into an agreement to acquire BioRexis Pharmaceutical Corp., a privately held biopharmaceutical company with several diabetes candidates and a novel technology platform for developing new protein drug candidates. Financial terms of the agreement were not disclosed. “Through this acquisition, we are investing in a company with an exciting new technology and potential new product candidates in diabetes,” said Edmund P. Harrigan, M.D., senior vice president, world...